CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

08 Mar 2024 09:25:24 By NetDania Notify

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

07 Mar 2024 09:12:48 By NetDania Notify

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

06 Mar 2024 08:45:06 By NetDania Notify

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

06 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

05 Mar 2024 09:02:57 By NetDania Notify

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

04 Mar 2024 10:25:20 By NetDania Notify

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

01 Mar 2024 08:48:44 By NetDania Notify

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

29 Feb 2024 13:30:15 By NetDania Notify

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

28 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 08:50:36 By Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

02 Feb 2024 15:01:11 By Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces Pricing of Public Offering

31 Jan 2024 08:19:41 By Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces Proposed Public Offering

30 Jan 2024 17:55:29 By Nasdaq GlobeNewswire

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

26 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

23 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

09 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

18 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

17 Oct 2023 07:00:00 By Nasdaq GlobeNewswire